WFH statement on recent developments related to hemophilia therapies
Despite advancements in care, people with hemophilia (PWH) still face major challenges around the world. Lack of access to care means that two-thirds of the global hemophilia population lacks treatment. Even in higher income countries, treatment is burdensome and breakthrough bleeding occurs. While recent therapies have addressed some critical needs, and commercialized gene therapies for hemophilia have shown encouraging, yet variable, results, a cure remains distant for most PWH. Continued innovation is essential to ensure better care for the global hemophilia community.